<DOC>
	<DOC>NCT03105102</DOC>
	<brief_summary>The study consists of 3 sub-studies, as follows: - Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety of risankizumab versus placebo as maintenance therapy in subjects with moderately to severely active Crohn's disease (CD) who responded to risankizumab induction treatment in Study M16-006 or Study M15-991 - Sub-study 2 (Randomized, exploratory maintenance study) to evaluate the efficacy and safety of two different dosing regimens for risankizumab as maintenance therapy in subjects who responded to induction treatment in Study M16-006 or Study M15-991; - Sub-study 3 (Open-label, long-term extension study) to evaluate long-term safety of risankizumab in subjects who completed Sub-study 1 or 2.</brief_summary>
	<brief_title>A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects who have completed Study M16006 or Study M15991 and have achieved clinical response Subject is considered by the Investigator, for any reason, to be an unsuitable candidate for the study Subject who has a known hypersensitivity to risankizumab or the excipients of any of the study drugs or the ingredients of CHO, or had an AE during Studies M16 006 or M15991 that in the Investigator's judgment makes the subject unsuitable for this study Subject is not in compliance with prior and concomitant medication requirements throughout Studies M16006 or M15991</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>ABBV-066</keyword>
	<keyword>risankizumab</keyword>
	<keyword>BI 655066</keyword>
</DOC>